ReviewCurrent opinion in biotechnology2025
Recent innovations in cannabinoid chemistry, biology, and biosynthesis.
Review in Current opinion in biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the Origin of Regioselectivity in Iron(III)-Promoted Friedel-Crafts Synthesis of Cannabinoids: Theoretical Studies and Synthetic Applications.The Journal of organic chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cannabis sativa and related plants are recognized for their psychoactive and therapeutic effects due to the unique molecules they produce, including phytocannabinoids. Beyond the major phytocannabinoids Δ⁹-tetrahydrocannabinol and cannabidiol, research on 'minor cannabinoids' has revealed new biological properties, motivating alternative production methods for these low-abundance molecules. Advances in asymmetric synthetic methods have enabled access to structurally complex cannabinoids and analogs. In tandem, synthetic biology approaches, including heterologous pathway reconstruction and functionally analogous enzyme discovery, have expanded the biosynthetic toolkit, delivering rare and novel cannabinoids at increasing scale. Here, we summarize the latest insights into cannabinoid pharmacology, synthetic chemistry innovations, and engineered production strategies, underscoring how feedback across disciplines is reshaping access to and understanding of minor cannabinoids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.